PSTX Stock Overview
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
Poseida Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.10|
|52 Week High||US$11.10|
|52 Week Low||US$1.83|
|1 Month Change||-34.78%|
|3 Month Change||-46.57%|
|1 Year Change||-77.96%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-86.32%|
Recent News & Updates
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
It's been a sad week for Poseida Therapeutics, Inc. ( NASDAQ:PSTX ), who've watched their investment drop 12% to...
|PSTX||US Biotechs||US Market|
Return vs Industry: PSTX underperformed the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: PSTX underperformed the US Market which returned -12.7% over the past year.
|PSTX Average Weekly Movement||13.5%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: PSTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: PSTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers.
Poseida Therapeutics Fundamentals Summary
|PSTX fundamental statistics|
Is PSTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PSTX income statement (TTM)|
|Cost of Revenue||US$19.76m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.31|
|Net Profit Margin||-442.92%|
How did PSTX perform over the long term?See historical performance and comparison
Is Poseida Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PSTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PSTX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: PSTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PSTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PSTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PSTX is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (1.5x).
How is Poseida Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PSTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PSTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PSTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PSTX's revenue (9.4% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: PSTX's revenue (9.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PSTX's Return on Equity is forecast to be high in 3 years time
How has Poseida Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PSTX is currently unprofitable.
Growing Profit Margin: PSTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PSTX is unprofitable, and losses have increased over the past 5 years at a rate of 32.9% per year.
Accelerating Growth: Unable to compare PSTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PSTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: PSTX has a negative Return on Equity (-139.55%), as it is currently unprofitable.
How is Poseida Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PSTX's short term assets ($190.5M) exceed its short term liabilities ($43.9M).
Long Term Liabilities: PSTX's short term assets ($190.5M) exceed its long term liabilities ($100.5M).
Debt to Equity History and Analysis
Debt Level: PSTX has more cash than its total debt.
Reducing Debt: PSTX's debt to equity ratio has increased from 16.6% to 55.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PSTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PSTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.4% each year
What is Poseida Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PSTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PSTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PSTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PSTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PSTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Gergen (58 yo)
Mr. Mark J. Gergen, J.D., has been Chief Executive Officer at Poseida Therapeutics, Inc. since February 01, 2022 and serves as its Director and served as Chief Business Officer of Poseida Therapeutics, Inc...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD2.82M) is above average for companies of similar size in the US market ($USD771.97K).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
Experienced Management: PSTX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: PSTX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PSTX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Poseida Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Poseida Therapeutics, Inc.
- Ticker: PSTX
- Exchange: NasdaqGS
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$131.680m
- Shares outstanding: 62.70m
- Website: https://www.poseida.com
Number of Employees
- Poseida Therapeutics, Inc.
- 9390 Towne Centre Drive
- Suite 200
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.